CounterACT Research Network

Abstracts for CounterACT projects are available via the CRISP database

Research Centers of Excellence

Gary R. Grotendorst, Ph.D.  
Lovelace Biomedical & Environmental Research Institute
Identification of Therapeutics for the Treatment of Sulfur Mustard Injury
Phage Display Screening for Antibody Ligands to Sulfur Mustard Protein Adducts *

Jeffrey D. Laskin, Ph.D.  
UMDNJ - Robert Wood Johnson Medical School
UMDNJ/Rutgers University CounterACT Research Center of Excellence
Polymer Nanogel Aggregates for Targeted Lung Delivery *

David E. Lenz, Ph.D.  
U.S. Army Medical Research Institute of Chemical Defense
Center for Catalytic Bioscavenger Medical Defense Research

Sadis Matalon, Ph.D.  
University of Alabama at Birmingham
Novel Treatments of Chlorine Induced Injury to the Cardio-Respiratory Systems

Steven Patterson, Ph.D.  
University of Minnesota Twin Cities Center for Drug Design
Combined Use of Cobinamide and a 3-Mercaptopyruvate Prodrug for Cyanide Poisoning

Carl W. White, M.D.
National Jewish Medical and Research Center
Novel Antioxidant Therapeutics for Sulfur Mustard Toxicity
Catalytic Antioxidants for Chlorine Gas Lung Toxicity  *

 

---

Individual Research Projects and Small Business Innovation Research

Edson X. Albuquerque, M.D., Ph.D.  
University of Maryland School of Medicine
Age and Sex Effects on Nerve Agent Damage to the Brain and Antidotal Therapies
Behavioral Effects of Low Doses of Nerve Agents Are Counteracted by Galantamine: Potential Molecular Mechanisms *

Tamas Bartfai, Ph.D.
Scripps Research Institute
Developing GalR1/2 Agonists to Treat Nerve Gas Induced Seizure

Gerry R. Boss, M.D.  
University of California, San Diego
Preclinical and Clinical Studies of Cobinamide, a New Cyanide Detoxifying Agent

Maria F.M. Braga, D.D.S., Ph.D.
Uniformed Services University of the Health Sciences
Efficacy of GluR5 Antogonists Against Soman-Induced Seizures and Neuropathology

John R. Cashman, Ph.D.
Human BioMolecular Research Institute
Biosensor for Real-Time Chemical Monitoring

William Catterall, Ph.D.  
University of Washington
Receptor Sites and Antagonists for Paralytic Neurotoxins
Scorpion Toxin Antagonists *

Robert J. DeLorenzo, M.D., Ph.D., M.P.H.  
Virginia Commonwealth University
Counter Measures Against Acetylcholine Receptor Activated Status Epilepticus
Development of BAPTA-AM as a Counteract Agent *

Raymond J. Dingledine, Ph.D.  
Emory University School of Medicine
Prostanoid Modulators that Reduce Brain Injury and Inflammation after Seizures

Marion F. Ehrich, Ph.D.  
VA-MD Regional College of Veterinary Medicine Virginia Tech
Fullerenes Counteracting Organophosphorus Threats

Pedro A. Ferchmin, Ph.D.  
Universidad Central del Caribe 
Protection Against Organophosphate Neurotoxins by Tobacco Cermbranoids

Byron D. Ford, Ph.D.  
Morehouse School of Medicine
Neuroprotective Roles for Neuregulins in Neurotoxin-Mediated Neuronal Injury

Richard K. Gordon, Ph.D.  
Walter Reed Army Institute of Research
Next Generation Oxime Therapeutic for Chemical Agent Inhibited CNS (Brain) ChEs

Kisholoy Goswami, Ph.D.
InnoSense, LLC
Fiber Grating-Based Chemoselective and Reversible Sensor Array

Michael D. Gunn, M.D.  
Duke University
Prevention of Inflammatory Lung Injury After Chlorine Exposure

Gary W. Hoyle, Ph.D.  
University of Louisville
Novel Therapies for Chlorine-Induced Lung Injury

Sven-Eric Jordt, Ph.D.
Yale University
Sensory Neural Mechanisms of Pulmonary Agent and Vesicant Toxicity

Jaideep Kapur, M.D., Ph.D.
University of Virginia HSC
Mechanism and Treatment of Nerve Agent-Induced Seizures

George D. Leikauf, Ph.D.  
University of Pittsburgh
Functional Genomics of Chemical -Induced Acute Lung Injury

Yuehe Lin, Ph.D.  
Battelle Pacific Northwest Laboratories
Innovative Biomonitoring Device for Rapid Diagnosis of Exposure to Nerve Agents

Oksana Lockridge, Ph.D.  
Eppley Inst. For Res. In Cancer/Allied Diseases
University of Nebraska Medical Center
Mass Spectrometry in Clinical Diagnosis of Nerve Agent Exposure

Michael C. MacLeod, Ph.D.  
University of Texas M.D. Anderson Cancer Center
Detoxification of Electrophilic Chemical Threat Agents by Nucleophilic Scavengers

Calum A. MaCrae, M.D., Ph.D.
Massachusetts General Hospital
Unbiased Screens in Zebrafish for New Classes of Cyanide Countermeasure

Sadis Matalon, Ph.D.  
University of Alabama at Birmingham
Prevention and Treatment of Chlorine Gas Induced Injury to the Pulmonary System

Mohammad Modarres-Zadeh, Ph.D.  
Cleveland Medical Devices Inc.
Field Deployable, Automatic, EEG Seizure Detector and Brain Dysfunction Monitor

Jon O. Nagy, Ph.D.  
Nagy Consulting
Development of a Selective Biosensor for Detecting Organophosphate Exposure

Madhusoodana Nambiar, Ph.D.
Walter Reed Army Institute of Research
Therapeutics Against Chemical Threat Induced Respiratory Toxicity

Steven Patterson, Ph.D.  
University of Minnesota Twin Cities
Center for Drug Design
Countermeasures Against Chemical Threats: Countermeasures Against Cyanide

James Peterson, Ph.D.  
University of Pittsburgh
Acute Cyanide Toxicity, Complex IV, NO, & Nitrite

Randall T. Peterson, Ph.D.
Massachusetts General Hospital
Rapid Development of in vivo Models for Countermeasure Discovery:Organophosphate

Matthew R. Redinbo, Ph.D.  
The University of North Carolina at Chapel Hill
Novel Protein-Based Therapeutics for Nerve Agent Detoxification
Exogenous Reactivators and Chemical Modifications of Designed Nerve Agent Hydrolyzing Human Carboxylesterase 1 Enzymes *  

Richard L. Rotundo, Ph.D.  
University of Miami Miller School of Medicine
Induced Therapeutic Overexpression of Acetylcholinesterase in vivo

David L. Sherman, Ph.D.  
Infinite Biomedical Technologies, LLC
Automated Seizure Detection Following Nerve Agent Exposure

Palmer W. Taylor, Ph.D.
University of California, San Diego
Oxime-Assisted Catalysis of Organophosphates and Reactivation of AChE
Enhancing the Efficacy of Butyrylcholinesterase as a Plasma Scavenging Agent *

John K. Troyer, Ph.D.  
PharmAthene, Inc.
Novel Therapeutic Agent to Treat Nerve Agent Exposure after Civilian Attack

James R. Wild, Ph.D.
Texas A&M University
Catalytic Bioscavengers with Broad Specificity Against OP Nerve Agents

Scott B. Wilson  
Persyst Development Corporation
A First-Responder EEG Device for Seizure Management in a Nerve Gas Attack

Ruben Boado, Ph.D.
ArmaGen Technologies, Inc.
Targeted Paraoxonase Fusion Protein as a Neurotherapeutic for Nerve Gas Agents

 

---

Contracts, Clinical Trials, and Inter-Agency Agreements

Carol Green, Ph.D., D.A.B.T.
SRI International
CounterACT Preclinical Development Facility

H. Steve White, Ph.D.
University of Utah
Anticonvulsant Screening Program - New Countermeasures Screening Services

Robert Silbergleit, MD
University of Michigan
Clinical Trial through NINDS Network
Intramuscular midazolam versus intravenous lorazepam in the pre-hospital treatment of status epilepticus (the RAMPART trial)

Jack M. Baggett, Ph.D.
US Army Medical Research Institute of Chemical Defense
Inter-Agency Agreement between the National Institutes of Health and the Department of Defense
Chemicals affecting skin, eyes & mucous membranes - toxic vesicants and industrial chemicals
Chemicals affecting the nervous system - anticonvulsants and neuroprotectants
Cyanide diagnostics and efficacy testing of next generation cyanide antidotes
Chemicals affecting the respiratory tract - pulmonary toxicants

---

* Supplemental research supported by the 2008 CounterACT Administrative Supplement Program (Please contact PI directly for additional information about these efforts).